Inmaculada Rioja
GlaxoSmithKline R&D
Stevenage, ENG, United Kingdom
Stevenage, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Bismuth Bicycles.
Journal: Journal of peptide science : an official publication of the European Peptide Society
Published: October 31, 2025
NLRP3 inflammasome-driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors.
Journal: Science advances
Published: July 09, 2025
Distinct H3K27 Methylation States Drive Cellular Responses to the Histone Demethylase Inhibitor GSK-J4 in Ovarian Cancer Cells.
Journal: Molecular cancer therapeutics
Published: March 12, 2025
Distinct H3K27 methylation states drive cellular responses to the histone demethylase inhibitor GSK-J4 in ovarian cancer cells.
Journal: Molecular cancer therapeutics
Published: March 12, 2025
Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787.
Journal: Journal of medicinal chemistry
Published: June 12, 2024
Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
Journal: Journal of medicinal chemistry
Published: November 15, 2023
Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432.
Journal: Journal of medicinal chemistry
Published: November 15, 2022
In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer.
Journal: British journal of cancer
Published: October 17, 2022
A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn's Disease.
Journal: Cells
Published: June 15, 2022
Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells.
Journal: Clinical epigenetics
Published: June 08, 2022
Essential Bromodomain TcBDF2 as a Drug Target against Chagas Disease.
Journal: ACS infectious diseases
Published: April 28, 2022
N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells.
Journal: Frontiers in endocrinology
Published: April 19, 2022
Last Updated: 09/26/2026